PMA 104RAlternative Names: PMA-104R
Latest Information Update: 18 Jul 2016
At a glance
- Originator Pharmedartis
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 18 Jul 2016 PMA 104R is still in preclinical development for Carcinoma, Pancreatic cancer, Prostate cancer and Solid tumours in Germany